1. Home
  2. NXRT vs AKBA Comparison

NXRT vs AKBA Comparison

Compare NXRT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXRT
  • AKBA
  • Stock Information
  • Founded
  • NXRT 2014
  • AKBA 2007
  • Country
  • NXRT United States
  • AKBA United States
  • Employees
  • NXRT N/A
  • AKBA N/A
  • Industry
  • NXRT Real Estate Investment Trusts
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NXRT Real Estate
  • AKBA Health Care
  • Exchange
  • NXRT Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • NXRT 776.2M
  • AKBA 729.1M
  • IPO Year
  • NXRT N/A
  • AKBA 2014
  • Fundamental
  • Price
  • NXRT $31.65
  • AKBA $1.66
  • Analyst Decision
  • NXRT Hold
  • AKBA Strong Buy
  • Analyst Count
  • NXRT 5
  • AKBA 6
  • Target Price
  • NXRT $37.33
  • AKBA $6.25
  • AVG Volume (30 Days)
  • NXRT 139.8K
  • AKBA 6.4M
  • Earning Date
  • NXRT 10-28-2025
  • AKBA 11-10-2025
  • Dividend Yield
  • NXRT 6.72%
  • AKBA N/A
  • EPS Growth
  • NXRT N/A
  • AKBA N/A
  • EPS
  • NXRT N/A
  • AKBA N/A
  • Revenue
  • NXRT $253,196,000.00
  • AKBA $225,071,000.00
  • Revenue This Year
  • NXRT N/A
  • AKBA $53.38
  • Revenue Next Year
  • NXRT $2.95
  • AKBA $30.53
  • P/E Ratio
  • NXRT N/A
  • AKBA N/A
  • Revenue Growth
  • NXRT N/A
  • AKBA 32.49
  • 52 Week Low
  • NXRT $29.93
  • AKBA $1.52
  • 52 Week High
  • NXRT $48.31
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • NXRT 52.46
  • AKBA 28.70
  • Support Level
  • NXRT $30.62
  • AKBA $1.57
  • Resistance Level
  • NXRT $32.36
  • AKBA $1.89
  • Average True Range (ATR)
  • NXRT 0.78
  • AKBA 0.16
  • MACD
  • NXRT 0.13
  • AKBA -0.06
  • Stochastic Oscillator
  • NXRT 68.72
  • AKBA 5.94

About NXRT NexPoint Residential Trust Inc.

NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: